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Abstract 
 
Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on 
several occasions during at least 3 weeks with uncertain diagnosis after a number of 
obligatory investigations. The differential diagnosis of FUO can be subdivided in four 
categories: infections, malignancies, non-infectious inflammatory diseases, and 
miscellaneous causes. In most cases of FUO, there is an uncommon presentation of 
a common disease. FDG-PET/CT is a sensitive diagnostic technique for the 
evaluation of FUO by facilitating anatomical localization of focally increased FDG 
uptake, thereby guiding further diagnostic tests to achieve a final diagnosis. FDG-
PET/CT should become a routine procedure in the work-up of FUO when diagnostic 
clues are absent. FDG-PET/CT appears to be a cost-effective routine imaging 
technique in FUO by avoiding unnecessary investigations and reducing the duration 
of hospitalization.   
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Introduction 
 
Fever of unknown origin (FUO) refers to a prolonged febrile illness without an 
established etiology despite intensive evaluation and diagnostic testing. The exact 
definition of FUO has been modified over time. In 1961, FUO was defined by 
Petersdorf and Beeson as an illness of more than three weeks duration with fever 
higher than 38.3°C (101°F) on several occasions and diagnosis uncertain after one 
week of study in the hospital 1. This definition has been changed in 1991 by removing 
the requirement that the evaluation must take place in the hospital and also by 
excluding immunocompromised patients, because these patients need a different 
approach in diagnosis and therapy 2. Later, the quantitative criterion of diagnosis 
uncertain after a period of time has been changed to a qualitative criterion that 
requires a number of diagnostic procedures to be performed 3 4 5. The current 
definition of FUO is: 1) temperature ≥38.3°C (101°F) on at least two occasions, 2) 
duration of illness ≥three weeks or multiple febrile episodes in ≥three weeks, 3) not 
immunocompromised (defined as neutropenia for at least one week in the three 
months prior to the start of the fever; known HIV-infection; known 
hypogammaglobulinemia or use of 10mg prednisone or equivalent for at least two 
weeks in the three months prior to the start of fever), and 4) uncertain diagnosis 
despite thorough history-taking, physical examination and the following 
investigations: erythrocyte sedimentation rate or C-reactive protein, hemoglobin, 
platelet count, leukocyte count and differentiation, electrolytes, creatinine, total serum 
protein, protein electrophoresis, alkaline phosphatase, aspartate aminotransferase, 
alanine aminotransferase, lactate dehydrogenase, creatine kinase, ferritin, 
antinuclear antibodies, rheumatoid factor, microscopic urinalysis, three blood 
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cultures, urine culture, chest X-ray, abdominal ultrasonography, and tuberculin skin 
test or interferon gamma release assay. FUO is closely related to inflammation of 
unknown origin (IUO) and causes and workup are the same for both FUO and IUO 6.   
 
The differential diagnosis of FUO can be subdivided in four categories: infections, 
malignancies, non-infectious inflammatory diseases (NIID), and miscellaneous 
causes 5 7. In Western countries, infections accounts for one-fifth of FUO cases, with 
next in frequency NIID and malignancies. In non-Western countries, infections 
(mostly tuberculosis) are a much more common cause of FUO (43% versus 17%) 
with similar cases due to NIID and malignancies 8. In most cases of FUO, there is an 
uncommon presentation of a common disease. Important for diagnosing FUO is a 
search for potentially diagnostic clues (PDCs) in a complete and repeated history-
taking, physical examination, and the essential investigations. PDCs are defined as 
all localizing signs, symptoms, and abnormalities potentially indicating a certain 
diagnosis. Based on these PDCs, a limited list of probable diagnosis can be made. 
Further diagnostic procedures should be limited to specific investigations to confirm 
or exclude these possible diseases, because most investigations are helpful only 
when performed in patients with PDCs for the diagnosis searched for. When PDCs 
are absent, FDG-PET/CT should be performed to guide additional diagnostic tests. In 
case negative FDG-PET/CT and persisting FUO, it is probably more rewarding to 
wait for new PDCs to appear than immediately performing more screening 
investigations.  
 
Focal inflammatory and infectious processes can be detected by radiologic imaging 
techniques, such as CT, MRI, and ultrasound. However, inflammatory and infectious 
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lesions can remain undetected, as substantial anatomic changes take time to 
develop and may be absent in an early phase. Distinction between active foci and 
residual changes due to cured processes or surgery is a limitation of these 
techniques. Also, these imaging techniques routinely provide information only on a 
part of the body.  
 
For FDG-PET, FDG accumulates in cells with an increased rate of glycolysis. All 
activated leukocytes (granulocytes, monocytes, and lymphocytes) demonstrate 
increased FDG uptake and delineation of acute and chronic inflammatory and 
infectious processes. The mechanism of FDG uptake in these activated leukocytes is 
related to the usage of glucose as the primary energy source only upon activation 
during the metabolic burst of these cells. FDG-PET can be used to evaluate disease 
throughout the body, but has limitations for assessment of the urinary tract due to 
FDG excretion into the urine, of the brain due to high accumulation of FDG, and 
potentially of the gastrointestinal tract due to diffuse or focal uptake as a result of 
peristalsis. In patients with fever, bone marrow uptake is frequently increased 
because of nonspecific activation of proliferating bone marrow cells due to 
interleukin-dependent up regulation of glucose transporters 9. In the myocardium, 
accumulation of FDG may be observed, which can be decreased by using a prior low 
carbohydrate fat allowed diet 10 11 and additional heparin preadministration 12.  
 
Compared to conventional scintigraphic techniques, FDG-PET has the advantages of 
higher resolution, higher sensitivity in chronic low-grade infections, and high accuracy 
in the central skeleton, as well as the short time period between injection of the 
radiopharmaceutical and the moment of imaging 13. Important disadvantages of 
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conventional scintigraphic methods, such as 67Ga-citrate scintigraphy and 111In- 
labeled or 99mTc-labeled leukocyte scintigraphy, are handling of potentially infected 
blood products (labeled leukocyte scintigraphy), high radiation burden (111In-labeled 
leukocyte and 67Ga-citratescintigraphy), instability of the labeling (99mTc-labeled 
leukocyte scintigraphy), and the relatively long timespan between injection and 
diagnosis (67Ga-citrate scintigraphy).  
 
Improved anatomical resolution by direct integration with CT (FDG-PET/CT) has 
further boosted the accuracy of FDG-PET/CT. Because FDG-PET/CT provides 
whole-body imaging in a single session with a relatively low radiation exposure, it 
plays an important role in the diagnosis of patients with FUO in clinical practice. Many 
studies on the value of FDG-PET and FDG-PET/CT in diagnosis of FUO have been 
published, often referring to the effectiveness of these imaging techniques in terms of 
sensitivity, specificity, and clinical helpfulness. However, calculating sensitivity and 
specificity in patients with FUO is difficult or even misleading due to the lack of a true 
gold standard. Also, in a relatively high number of patients, a final diagnosis cannot 
be established and nonspecific FDG-uptake could lead to false-positive findings and 
to shortcomings in follow-up of these findings. Therefore, in FUO it is more useful to 
investigate the clinical helpfulness of FDG-PET and FDG-PET/CT rather than 
sensitivities and specificities 9. FDG-PET/CT is helpful when the FDG-PET/CT 
contributes to the final causal diagnosis of FUO.   
 
FDG-PET/CT in FUO in adults 
Before introduction of PET/CT, the value of stand-alone FDG-PET (without combined 
CT) has been studied in patients with FUO 14-22 23. These studies showed FDG-PET 
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to be a valuable diagnostic technique in patients with FUO with a helpfulness of FDG-
PET in 16-69% of patients. Figure 1 shows an example of an FDG-PET/CT in a 
patient with FUO due to non-infectious vasculitis of the large arteries, subsequently 
treated with cortoicosteroids. Figure 2 depicts the FDG-PET/CT of a septic patient 
due to vascular graft infection, treated with a prolonged course of antibiotics. 
However, comparing these studies was rather difficult, due to a different definition of 
FUO in these studies and also in some studies a (highly) selected patient population. 
In general, in these studies, FDG-PET was often performed without using a 
structured diagnostic protocol, and therefore at different stages of the process of 
FUO. Bleeker-Rovers et al. 5 have already shown that using such a structured 
diagnostic protocol including FDG-PET reduces the chance of selection bias.  
 
After the introduction of FDG-PET combined with CT, the diagnostic value of FDG-
PET/CT has been investigated in one prospective study and in 15 retrospective 
studies in 823 patients with FUO (Table 1) 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39.The 
only prospective study on the value of FDG-PE/CT performed in patients with FUO is 
the study of Keidar et al. 24. In this study, 48 patients were included. FDG-PET/CT 
identified the underlying etiology of FUO in 22 patients (46%). FDG-PET/CT 
contributed clinically important information to the diagnosis of exclusion of a focal 
etiology in 90% of cases. Balink et al. 25 retrospectively included 68 patients with 
FUO. FDG-PET/CT was helpful in 56% and in 93% of positive studies, FDG-PET/CT 
led to the causal source of FUO either by identifying the etiology of the FUO or by 
guiding further management, including invasive therapeutic procedures. Federici et 
al. 26 investigated the value of FDG-PET/CT in ten patients with FUO and four 
patients with unexplained inflammatory syndrome without fever. FDG-PET/CT was 
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helpful in 50% of patients with FUO. Ferda et al. 27 performed a retrospective study 
on 48 patients with FUO. The authors concluded FDG-PET/CT to be helpful in 54% 
of cases. The study of Kei et al. 28 in 12 patients with FUO showed FDG-PET/CT to 
be helpful in 42%. Sheng et al. 29 included 48 patients with FUO and FDG-PET/CT 
was helpful in 67% of cases. In 36 patients (75%), a final diagnosis was established 
and in 89% of these patients FDG-PET/CT contributed to this diagnosis. The study 
on 24 patients with FUO of Pelosi et al. 30 showed FDG-PET/CT to be helpful in 46%. 
Pedersen et al. 31 retrospectively included 22 patients with FUO. In these patients, 
FDG-PET/CT successfully identified the cause of FUO in 45%. Crouzet et al. 32 
investigated the value of FDG-PET/CT in 79 patients with FUO. Overall, FDG-
PET/CT was helpful in 57%. Of all patients with a final diagnosis, FDG-PET/CT 
contributed to the final diagnosis in 74%. The retrospective study of Kim et al. 33 in 48 
patients with FUO, showed FDG-PET/CT to be helpful in 52%. An Indian 
retrospective study on 103 patients with FUO of Manohar et al. 38 investigated the 
role of FDG-PET/CT and concluded FDG-PET/CT to be helpful in 60% of patients. Of 
all 63 patients with a final diagnosis, FDG-PET/CT contributed to this diagnosis in 
98% of these patients. Tokmak et al. 34 retrospectively included 21 patients with FUO 
and in these patients FDG-PET/CT was helpful in 60%. Buch-Olsen et al. 39 showed 
FDG-PET/CT to be helpful in 53% of 57 patients with FUO. Singh et al. 35 included 47 
patients with FUO and FDG-PET/CT was helpful in 38% of patients. In this study, a 
final diagnosis could be established in 53% of patients. The largest retrospective 
study performed on the value of FDG-PET/CT in FUO is of Gafter-Gvili et al. 37 
including 112 patients with FUO. The authors concluded FDG-PET/CT to be helpful 
in 46% of all patients. Recently, Pereiria et al. 36 investigated the role of FDG-PET/CT 
in 76 patients of FUO. FDG-PET/CT was helpful in 60% of patients. Overall clinical 
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helpfulness of all studies investigating FDG-PET/CT in FUO, corrected for study 
population, was 55%. Recently, Hung et al. 40 retrospectively included 58 patients 
with FUO who both underwent FDG-PET/CT and 67Ga-SPECT/CT within 7 days from 
each other. FDG-PET/CT was helpful in 57% of patients versus 33% for 67Ga-
SPECT/CT (p<0.05).  
 
As in studies on the value of FDG-PET, comparing these studies is difficult. The 
definition of FUO was not further specified in six studies 25 27 29 30 32 33 39. In general, 
the exact definition of FUO varies in all studies (Table 1). In the study of Pereira et 
al., immunocompromised patients were also included 36, although these patients 
need a different approach and are difficult to compare with non-immunocompromised 
patients with FUO. In most studies no follow-up term was mentioned. Also, because 
the majority of these studies were retrospective, inclusion bias cannot be excluded as 
patients with negative findings on conventional imaging techniques are more likely to 
undergo FDG-PET/CT than patients with positive findings. The difference in timing of 
FDG-PET/CT as well as the selection of patients could affect the calculation of 
clinical helpfulness.  
 
FDG-PET/CT in children with FUO 
The value of FDG-PET/CT has also been studied in children with FUO. Jasper et al. 
investigated the value of 47 FDG-PET scans and 30 FDG-PET/CT in 69 children with 
FUO 41. The mean age of these children was 8.1 years (range 0.2-18.1 years). Of the 
30 FDG-PET/CT scans performed, 17 scans were performed because of FUO and 
13 scans were performed because of inflammation of unknown origin without fever. 
Of the 17 FDG-PET/CT scans performed because of FUO, 24% of FDG-PET/CT 
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scans were helpful. Of 13 FDG-PET/CT scans performed in IUO patients, 46% of 
FDG-PET/CT scans were helpful. In a retrospective study of 31 children with FUO, 
Blokhuis et al. analyzed three FDG-PET scans and 28 FDG-PET/CT scans 42. The 
mean age of the children was 8.1 years with a range of 0-16 years. FDG-PET/CT 
was helpful in 29% (8 out of 28 FDG-PET/CT scans). Chang et al. performed a 
retrospective study in 19 critical ill children with FUO who required intensive care 
support. The mean age of the children was 5.7 years (range 0-14 years) 43. All 
patients underwent FDG-PET/CT and FDG-PET/CT was helpful in 84% of children. 
Of 16 children with final diagnosis of FUO and helpful FDG-PET/CT, 9 diagnoses 
(56%) were infectious, 2 (13%) were NIID related, 3 (19%) were malignancy related, 
and 2 (13%) were miscellaneous.    
 
Comparing these studies is again difficult as they used a different definition of FUO. 
Also, Jasper et al. considered some of the negative FDG-PET/CT results useful 41, 
although a negative FDG-PET/CT scan is only helpful in excluding focal disease, but 
does not contribute to the diagnosis of the underlying cause of the fever. The children 
in the study of Chang et al. underwent aggressive diagnostic and imaging workup 
due to their critical illness, which could declare the high proportion of helpful FDG-
PET/CT scans 43.  
 
FDG-PET/CT in FUO in specific patient groups 
The value of FDG-PET/CT in FUO has also been investigated in specific patient 
groups. Although immunocompromised patients were excluded of the classic 
definition of FUO, two studies investigated the role of FDG-PET/CT in HIV-positive 
patients with prolonged fever. Castaigne et al. retrospectively studied ten patients 
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with HIV-associated prolonged fever who underwent FDG-PET/CT 44. In nine out of 
these ten patients, FDG-PET/CT was helpful. Tuberculosis was diagnosed in six 
patients and three patients had a neoplasm (lymphoma in two patients, Kaposi's 
sarcoma in one patient). Mean CD4 count in these patients was 128 cells/ml (range 
13-400 cells/ml). A prospective study of 20 HIV-positive patients with prolonged fever 
compared with ten HIV-positive asymptomatic but viraemic patients was performed 
by Martin et al 45. Mean CD4 count in patients with prolonged fever was 60 cells/ml 
(range 1-566) and 268 cells/ml (range 209-335) in patients without prolonged fever. 
Both patient groups underwent FDG-PET/CT. In the HIV-positive patients with 
prolonged fever, FDG-PET/CT was abnormal in all patients. Sixteen patients (80%) 
had focal lesions on FDG-PET/CT: eight patients were diagnosed with tuberculosis, 
three patients had lymphoma, three patients had nontuberculous mycobacteriosis, 
one patient had a pneumococcal infection, and one patient had dental infection. The 
four patients without focal FDG-uptake had drug-induced fever (three patients) and 
visceral disseminated leishmaniasis (one patient). All 20 HIV-positive patients with 
prolonged fever had abnormal FDG-uptake in peripheral or central lymph nodes. Of 
all ten HIV-positive patients without prolonged fever, FDG-PET/CT was abnormal in 
nine patients with hyper metabolic peripheral lymph nodes in all nine patients. 
SUVmax of peripheral lymph nodes of patients with fever was significantly higher 
compared to SUVmax in patients without fever. These studies showed that FDG-
PET/CT could be helpful in HIV-positive patients with prolonged fever.  
FDG-PET/CT has been studied in patients on hemodialysis. A retrospective study 
investigated the value of FDG-PET/CT in 20 patients on dialysis with prolonged fever 
46. FDG-PET/CT was helpful in 75% of patients. 
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FDG-PET/CT and CRP levels in FUO 
Bleeker-Rovers et al. showed that FDG-PET (without combined CT) did not 
contribute to the final diagnosis of FUO in case of normal C-reactive protein (CRP) 
and/or erythrocyte sedimentation rate (ESR) 20. In a large retrospective study on 498 
patients with FUO and inflammation of unknown origin, the predictive value of CRP 
and ESR to a positive FDG-PET/CT result was determined 47. ESR values were 
available in 72% of patients, CRP values were available in all patients. A final 
diagnosis was established in 331 of 498 patients and FDG-PET/CT had a diagnostic 
accuracy of 89%. In this study, no optimal cutoff value for CRP could be made. 
Elevated CRP levels reflected the presence and degree of inflammation more truly 
compared to ESR levels. FDG-PET/CT was 100% true negative only in patients with 
CRP levels less than 5 mg/l. Another retrospective study on 76 patients with FUO 
showed FDG-PET/CT to be helpful and contributory for the diagnosis of FUO when 
patients had higher levels of CRP and ESR 48. A recent retrospective study on 223 
FDG-PET/CT scans performed in 151 patients with FUO showed an overall 
helpfulness of FDG-PET/CT in 24.1% of all patients. The presence of fever on the 
day of FDG-PET/CT or the presence of elevated CRP within seven days before FDG-
PET/CT increased the diagnostic value significantly to 70 % and 47 %, respectively 
(data on file).  
 
Cost-effectiveness of FDG-PET/CT in FUO  
Given the large number of FDG-PET/CT studies in patients with FUO, it is of interest 
to assess the cost-effectiveness of FDG-PET/CT in FUO patients. One Spanish study 
has been published on the cost-effectiveness of FDG-PET/CT in FUO 49. In this study 
on 20 patients, the mean cost per patient of the diagnostic procedures preceding 
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FDG-PET/CT was €11,167, including an average of 11 days of hospitalization and 
outpatient checks. If FDG-PET/CT had been performed earlier in the diagnostic 
process, €5,471 per patient would have been saved on diagnostic tests and 
hospitalization days. Besides this study, one cost-effectiveness pilot study on FDG-
PET/CT in patients with inflammation of unknown origin has been published 50. In this 
retrospective study, 46 patients with inflammation of unknown origin who underwent 
FDG-PET/CT were compared with 46 patients with inflammation of unknown origin 
without FDG-PET/CT. In patients who underwent FDG-PET/CT, a final diagnosis was 
established in 32 patients (70%). Estimated mean cost per patient of all diagnostic 
procedures with FDG-PET/CT was €1,821. When adding the cost of mean number of 
hospitalization days per patient (6.9 days, range 0-32 days), the mean cost increased 
to €5,298 per patient. In patients without FDG-PET/CT, a diagnosis was reached in 
14 patients (30%). Estimated mean cost per patient of all diagnostic procedures 
without FDG-PET/CT was €2,051. When adding the cost of mean number of 
hospitalization days per patient (21 days, range unknown), the mean cost increased 
to €12,614 per patient. It was concluded that FDG-PET/CT has the potential to 
become a cost-effective routine imaging technique for further diagnostic decision 
making by avoiding unnecessary, invasive and expensive investigations and by 
reducing the duration of hospitalization. An important limitation of this study was the 
fact that the patient group without FDG-PET/CT was a published dataset from a 
French study. So the patient groups were selected in different time periods and also 
in different countries which inevitably led to selection bias. However, an important 
conclusion was the significantly higher mean cost per patient and also the longer 
duration of hospitalization in the patient group without FDG-PET/CT compared to 
patients who did undergo FDG-PET/CT.  
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Conclusions 
 
FDG-PET/CT is a helpful technique in diagnosing FUO in both adults and children. 
Therefore, FDG-PET/CT should become a routine procedure in the work-up of FUO 
when diagnostic clues are absent. FDG-PET/CT appears to be a cost-effective 
routine imaging technique in FUO by avoiding unnecessary investigations and 
reducing the duration of hospitalization and should be performed when fever is 
present or within one week in case of elevated CRP.  
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Table 1. Review of the literature on FDG-PET/CT in patients with FUO 
Reference Study design 
(no. of patients) 
FUO definition  
 
Helpfulness 
FDG-PET/CT  
 
Keidar  
2008 24 
Prospective  
(48) 
Fever > 38.3°C > 3 wk; no diagnosis 
after 1 wk of in-patient investigations 
46% 
Balink  
2009 25 
Retrospective  
(68) 
Not specified 
56% 
Federici  
2010 26 
Retrospective  
(10) 
Fever > 38.3°C > 3 wk; no diagnosis 
after 1 wk of in-patient investigations 
50% 
Ferda  
2010 27 
Retrospective  
(48) 
Not specified 
54% 
Kei  
2010 28 
Retrospective  
(12) 
Fever > 38.3°C > 3 wk; no diagnosis 
after > 3 d in-patient investigations or 2 
wk out-patient investigations 
42% 
Sheng  
2011 29 
Retrospective  
(48) 
Not specified 
67% 
Pelosi  
2011 30 
Retrospective  
(24) 
Not specified 
46% 
Pedersen  
2012 31 
Retrospective  
(22) 
Fever > 38.3°C > 3 wk; no diagnosis 
after 3 d of in-patient investigations 
45% 
Crouzet  
2012 32 
Retrospective  
(79) 
Not specified 
75% 
Kim  
2012 33 
Retrospective  
(48) 
Not specified 
52% 
Manohar  
2013 38 
Retrospective  
(103) 
Fever > 38.3°C > 3 wk; no diagnosis 
after > 1 wk of in-patient or out-patient 
investigations 
60% 
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Tokmak  
2014 34 
Retrospective  
(21) 
Fever > 38.3°C > 3 wk; no diagnosis 
after > 1 wk of in-patient investigations 
60% 
Buch-Olsen  
2014 39 
Retrospective  
(57) 
Not specified 
53% 
Singh  
2015 35 
Retrospective  
(47) 
Fever > 38.3°C > 3 wk; no diagnosis 
after > 1 wk of in-patient investigations 
38% 
Gafter-Gvili  
2015 37 
Retrospective  
(112) 
Fever > 38.3°C > 3 wk; no diagnosis 
after > 1 wk of in-patient or out-patient 
investigations  
46% 
Pereira  
2016 36 
Retrospective  
(76) 
Fever > 38.3°C > 3 wk 
60% 
Hung  
2017 40 
Retrospective 
(58) 
Fever > 38.3°C > 3 wk; no diagnosis 
after > 1 wk of in-patient investigations 
57% 
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Figures 
 
Figure 1. 
A 60-year-old woman presented with fever, night sweats, and arthralgia. Physical 
examination was normal. ESR was 125 mm/hour and leukocyte count was 12.4 x 
109/l with normal creatinine level and liver function tests. FDG-PET/CT showed highly 
increased FDG uptake of the aorta, subclavian arteries, and femoral arteries. She 
was diagnosed with large vessel vasculitis. Her symptoms resolved and ESR 
normalized upon treatment with corticosteroids.  
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Figure 2. 
A 75-year-old man, with a medical history of an aortic vascular prosthesis due to a 
symptomatic aneurysm and metastatic prostate carcinoma, presented with fever and 
night sweats. Physical examination was normal. CRP was 130 mg/L and leukocyte 
count was 11.0 x 109/l with normal creatinine level but increased AF (220 U/L) and 
LDH (771 U/L). FDG-PET/CT showed besides the known metastatic prostate 
carcinoma infection of the aortic graft. Blood cultures were positive for Streptococcus 
anginosus and the patient was treated with amoxicillin/clavulanic acid  until his death 
6 months later.  
 
 
